Vancouver, British Columbia – April 24, 2026 – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (“SureNano” or the “Company”), parent company of GlucaPharm Inc. (“GlucaPharm”), a biopharmaceutical company developing novel therapeutic multi-receptor GLP-1 agonist peptide for the treatment of Type II Diabetes and Obesity candidates, today announced the planning of a comprehensive U.S. Food and Drug Administration (FDA) pathway Investigational New […]
SureNano Science Ltd. Acquires GlucaPharm Inc.,Advancing Second-Generation FDA Pathway GLP-1 Drug Development
Vancouver, British Columbia – February 23, 2026 – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (“SureNano” or the “Company”) is pleased to announce that it has completed the acquisition of GlucaPharm Inc. (“GlucaPharm”), a next-generation glucagon-like peptide (“GLP”) pharmaceutical company developing a patented therapeutic candidate designed to address obesity and metabolic disease with improved tolerability and delivery potential. The acquisition […]